Received Nov 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | B5NJ9 | IM / LA |
experience a mild shock sensation in both of his legs and toes; This non-serious case was reported by a consumer via call center representative and described the occurrence of sensory loss in a 69-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number B5NJ9, expiry date 05-DEC-2026) for prophylaxis. Concomitant products included hydrocodone. On 31-OCT-2025, the patient received Arexvy (intramuscular, left arm) .5 ml. On 01-NOV-2025, 1 days after receiving Arexvy, the patient experienced sensory loss (Verbatim: experience a mild shock sensation in both of his legs and toes). The patient was treated with methylprednisolone. The outcome of the sensory loss was not resolved. It was unknown if the reporter considered the sensory loss to be related to Arexvy. It was unknown if the company considered the sensory loss to be related to Arexvy. Additional Information: GSK Receipt Date: 04-NOV-2025 The patient self-reported this case for himself. The patient received a RSV vaccine on Friday October 31, 2025. The patient could not provide the Brand name / Manufacturer of the vaccine at this time. On Saturday, 1 November 2025, the patient begins to experience a mild shock sensation in both of his legs and toes. When the patient touches the back of his neck, he experiences the shock sensation. The patient will also experience the shock sensation independent of touching his neck. On Sunday 2 November 2025, the patient went to the emergency room for treatment as the sensation was getting worse. He was prescribed Methylprednisolone 4mg as a tapering dose. To this point the Methylprednisolone has not been effective. Blood work was also done while in the emergency room. The patient will gather and provide further information regarding the vaccine.
HYDROCODONE